Repligen Corporation filed a current report on September 15, 2026, disclosing that director Karen A. Dawes notified the company on September 10, 2026, of her planned retirement from the Board of Directors, effective September 30, 2026.

Key Highlights

  • Retirement notice date: Karen A. Dawes informed Repligen of her intent to retire on September 10, 2026.
  • Effective date: Her departure from the Board is effective September 30, 2026.
  • Tenure: Ms. Dawes served on the Repligen Board for over twenty years, according to the filing.
  • No disagreement: The filing states her decision is "not the result of any disagreement with Repligen with respect to Repligen's operations, policies or procedures."
  • Signed by CEO: The report was signed by Olivier Loeillot, President and Chief Executive Officer of Repligen Corporation.

Repligen Director Departure After More Than Two Decades of Board Service

According to the filing, Karen A. Dawes notified Repligen Corporation, a Delaware-incorporated bioprocessing technology company trading on the Nasdaq Global Select Market under the symbol NASDAQ:RGEN, that she will retire from its Board of Directors after more than twenty years of service. The filing was submitted under Item 5.02, which covers departures and appointments of directors and certain officers.

The filing includes a statement attributed to Ms. Dawes: "It has been a privilege and an honor to serve on Repligen's Board and to contribute to the Company's transformation over the years. With a successful CEO transition complete, I believe now is the right time for my retirement." The filing further notes that she expressed confidence in the company's "outstanding leadership team and Board" and its positioning for "its next phase of growth." These characterizations are Ms. Dawes's own and appear in the filing as her direct quotation.

Repligen disclosed that Ms. Dawes's retirement is voluntary and unrelated to any operational or policy dispute with the company. The report was filed on September 15, 2026, and signed by Olivier Loeillot in his capacity as President and Chief Executive Officer, reflecting a completed CEO transition that Ms. Dawes referenced in her statement. No replacement director or board restructuring was announced in this filing.

What Was Disclosed

Repligen Corporation disclosed the planned retirement of long-serving board member Karen A. Dawes, effective September 30, 2026, confirming no disagreement with company operations, policies, or procedures prompted her decision.